<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  Nanotechnology-Enabled Implant for Controlling Intraocular Pressure</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>07/01/2019</AwardEffectiveDate>
<AwardExpirationDate>06/30/2020</AwardExpirationDate>
<AwardTotalIntnAmount>225000.00</AwardTotalIntnAmount>
<AwardAmount>225000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Henry Ahn</SignBlockName>
<PO_EMAI>hahn@nsf.gov</PO_EMAI>
<PO_PHON>7032927069</PO_PHON>
</ProgramOfficer>
<AbstractNarration>This SBIR Phase I project aims to improve the surgical treatment used for patients suffering from open angle glaucoma (OAG), through the development and testing of the world's thinnest ocular implant. OAG is the most common form of glaucoma, the leading cause of irreversible blindness in the world. By 2020, glaucoma will affect 3.4 million people in the U.S. and 80 million people globally. In the U.S., glaucoma incurs over $4 billion in medical and societal costs per year. For patients with glaucoma, elevated eye pressure must be lowered to protect the optic nerve from damage. However, conventional surgical implant treatments are bulky, highly invasive, and cause chronic discomfort. While newer, smaller devices are less invasive, they present issues with long-term efficacy as they inadequately sustain lower eye pressure when scarring occurs. This project will develop an implant many times thinner than a human hair to safely reduce eye pressure while minimizing the risk of patient discomfort and failure from scarring. The nanotechnology-enabled device will be designed to facilitate biocompatibility, patient comfort, and physician insertion through a combination of mechanical and materials engineering. Beyond the application in glaucoma, the technology developed will play a key role in future permanent and efficacious ocular implants - a rapidly growing component of vision care.&lt;br/&gt;&lt;br/&gt;This innovation involves careful engineering of the materials composition and microarchitecture of an ultrathin implant to treat glaucoma. Specifically, the project will optimize a novel corrugated microstructure for a unique combination of mechanical and fluid flow properties. Specific corrugations will provide the stiffness required for handling by physicians, as well as the flexibility to conform to soft eye tissues. Microchannels from the corrugations will also be patterned to provide adequate flow for reducing intraocular pressure, while providing enough resistance to prevent overly low pressure. Microscale architecture and materials will first be engineered through experimental testing of tensile stiffness, bending stiffness, shear strength, aqueous stability, and pressure flow characteristics. The implant with the optimal materials microarchitecture will subsequently be studied in an in vivo leporine eye model. This study will monitor intraocular pressure, scar tissue formation, levels of inflammation, adverse events, and implant stability. Together, the bench and pre-clinical tests will provide critical data for further refinement of this implant and facilitate progress towards realizing an optimal defense against blindness.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>06/24/2019</MinAmdLetterDate>
<MaxAmdLetterDate>07/26/2019</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>1913441</AwardID>
<Investigator>
<FirstName>Samuel</FirstName>
<LastName>Nicaise</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Samuel Nicaise</PI_FULL_NAME>
<EmailAddress>samnicaise@gmail.com</EmailAddress>
<PI_PHON>8594683276</PI_PHON>
<NSF_ID>000792683</NSF_ID>
<StartDate>06/24/2019</StartDate>
<EndDate>07/26/2019</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Georgia</FirstName>
<LastName>Griggs</LastName>
<PI_MID_INIT>E</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Georgia E Griggs</PI_FULL_NAME>
<EmailAddress>Georgia@avisitech.com</EmailAddress>
<PI_PHON>7036382964</PI_PHON>
<NSF_ID>000805534</NSF_ID>
<StartDate>07/26/2019</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Avisi Technologies, Inc</Name>
<CityName>Philadelphia</CityName>
<ZipCode>191462701</ZipCode>
<PhoneNumber>9492941086</PhoneNumber>
<StreetAddress>3401 GRAYS FERRY AVE</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Pennsylvania</StateName>
<StateCode>PA</StateCode>
<CONGRESSDISTRICT>02</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>PA02</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>081325855</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>AVISI TECHNOLOGIES, INC</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[AVISI TECHNOLOGIES, LLC]]></Name>
<CityName>Philadelphia</CityName>
<StateCode>PA</StateCode>
<ZipCode>191462701</ZipCode>
<StreetAddress><![CDATA[3401 Grays Ferry Ave]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Pennsylvania</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>03</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>PA03</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>5371</Code>
<Text>SMALL BUSINESS PHASE I</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<Appropriation>
<Code>0119</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2019~225000</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p><span id="docs-internal-guid-fd52a787-7fff-3855-9de7-809256827aa9"> <p dir="ltr"><span>Project Outcomes Report &ndash; NSF Award </span><span>#1913441</span></p> <p dir="ltr"><span>Project Title: </span><span>SBIR Phase I: Nanotechnology-Enabled Implant for Controlling Intraocular Pressure</span></p> <p dir="ltr"><span>Recipient Organization: Avisi Technologies</span></p> <p dir="ltr"><span>Project/Grant Period: July 1, 2019 - June 30, 2020</span></p> <p dir="ltr"><span>PI: Georgia Griggs, MSE</span></p> <br /> <p dir="ltr"><span>Project Outcomes Report</span></p> <br /> <p dir="ltr"><span>This project enabled the development and established the feasibility of VisiPlate. VisiPlate is a nanotechnology-enabled intraocular implant designed to treat glaucoma by reducing intraocular pressure. Intraocular pressure remains the only modifiable risk factor in treating glaucoma, a leading cause of irreversible blindness that affects 80 million patients worldwide.</span></p> <p dir="ltr"><span>Feasibility of the use of VisiPlate as a surgical implant was demonstrated through validations of mechanical strength, flow compatibility, and safe and effective performance </span><span>in vivo. </span><span>Therefore, this project provided critical feasibility data that will support a future FDA&nbsp; submission for VisiPlate as a medical device to treat glaucoma.</span></p> <br /> <p dir="ltr"><span>This project guided design improvements and demonstrated key safety and performance features of VisiPlate. VisiPlate was characterized mechanically across a multitude of factors including: tensile strength, shear, modulus, and integrity in an aqueous environment. Overall, it was determined that VisiPlate can successfully withstand the rigors of surgical insertion and maintain integrity when exposed to an aqueous environment and physiological forces. VisiPlate&rsquo;s channel dimensions were optimized to achieve flow characteristics ideal for lowering and controlling pressure. Additionally, the biocompatibility and feasibility of the VisiPlate ultra-thin shunt was tested in a rabbit eye model. This study involved implanting VisiPlate units in live rabbits and monitoring three rabbits over three months and three rabbits over six months. VisiPlate prototypes were well tolerated in all subjects, caused minimal inflammatory response, and showed efficacy in lowering intraocular pressure from baseline over the study period. Optical coherence tomography and slit lamp photography also confirmed that there was no implant migration, wound leakage, or adverse events.&nbsp;</span></p> <p dir="ltr"><span>&nbsp;</span></p> <p dir="ltr"><span>In addition to accomplishing project goals, this work helped Avisi identify areas for process refinement as more VisiPlates are fabricated for pre-clinical and clinical testing. In the future, Avisi will build upon the findings in this project to refine the manufacturing process, gather more robust safety and efficacy data, and ultimately create clinic-ready prototypes supported by robust data that will enable FDA approval.&nbsp;</span></p> <br /> <p dir="ltr"><span>With the support of the NSF, Avisi has successfully prototyped, tested, and improved a novel surgical implant that will improve quality of life for millions. VisiPlate is a safer and more efficacious solution positioned to alleviate the global burden of blindness from glaucoma.</span></p> <br /> <p dir="ltr"><span>*This Project Outcomes Report for the General Public is displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed in this Report are those of the PI and do not necessarily reflect the views of the National Science Foundation; NSF has not approved or endorsed its content.</span></p> <div><span><br /></span></div> </span></p> <p>&nbsp;</p><br> <p>            Last Modified: 04/24/2020<br>      Modified by: Georgia&nbsp;E&nbsp;Griggs</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[  Project Outcomes Report &ndash; NSF Award #1913441 Project Title: SBIR Phase I: Nanotechnology-Enabled Implant for Controlling Intraocular Pressure Recipient Organization: Avisi Technologies Project/Grant Period: July 1, 2019 - June 30, 2020 PI: Georgia Griggs, MSE   Project Outcomes Report   This project enabled the development and established the feasibility of VisiPlate. VisiPlate is a nanotechnology-enabled intraocular implant designed to treat glaucoma by reducing intraocular pressure. Intraocular pressure remains the only modifiable risk factor in treating glaucoma, a leading cause of irreversible blindness that affects 80 million patients worldwide. Feasibility of the use of VisiPlate as a surgical implant was demonstrated through validations of mechanical strength, flow compatibility, and safe and effective performance in vivo. Therefore, this project provided critical feasibility data that will support a future FDA  submission for VisiPlate as a medical device to treat glaucoma.   This project guided design improvements and demonstrated key safety and performance features of VisiPlate. VisiPlate was characterized mechanically across a multitude of factors including: tensile strength, shear, modulus, and integrity in an aqueous environment. Overall, it was determined that VisiPlate can successfully withstand the rigors of surgical insertion and maintain integrity when exposed to an aqueous environment and physiological forces. VisiPlateâ€™s channel dimensions were optimized to achieve flow characteristics ideal for lowering and controlling pressure. Additionally, the biocompatibility and feasibility of the VisiPlate ultra-thin shunt was tested in a rabbit eye model. This study involved implanting VisiPlate units in live rabbits and monitoring three rabbits over three months and three rabbits over six months. VisiPlate prototypes were well tolerated in all subjects, caused minimal inflammatory response, and showed efficacy in lowering intraocular pressure from baseline over the study period. Optical coherence tomography and slit lamp photography also confirmed that there was no implant migration, wound leakage, or adverse events.    In addition to accomplishing project goals, this work helped Avisi identify areas for process refinement as more VisiPlates are fabricated for pre-clinical and clinical testing. In the future, Avisi will build upon the findings in this project to refine the manufacturing process, gather more robust safety and efficacy data, and ultimately create clinic-ready prototypes supported by robust data that will enable FDA approval.    With the support of the NSF, Avisi has successfully prototyped, tested, and improved a novel surgical implant that will improve quality of life for millions. VisiPlate is a safer and more efficacious solution positioned to alleviate the global burden of blindness from glaucoma.   *This Project Outcomes Report for the General Public is displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed in this Report are those of the PI and do not necessarily reflect the views of the National Science Foundation; NSF has not approved or endorsed its content.             Last Modified: 04/24/2020       Submitted by: Georgia E Griggs]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
